<?xml version='1.0' encoding='utf-8'?>
<document id="15801541"><sentence text="Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors."><entity charOffset="37-44" id="DDI-PubMed.15801541.s1.e0" text="lactone" /></sentence><sentence text="To gain a better understanding of the metabolic properties between the open acid and lactone form of HMG-CoA reductase inhibitors (statins), the paper focused primarily on characterizing the metabolic properties of statins"><entity charOffset="85-92" id="DDI-PubMed.15801541.s2.e0" text="lactone" /></sentence><sentence text=" We compared the metabolism of the acid and lactone forms of several statins, including atrovastatin, simvastatin, cerivastatin fluvastatin, pitavastatin and rosuvastatin with respect to metabolic clearance, CYP enzymes involved and drug-drug interactions"><entity charOffset="44-51" id="DDI-PubMed.15801541.s3.e0" text="lactone" /><entity charOffset="88-100" id="DDI-PubMed.15801541.s3.e1" text="atrovastatin" /><entity charOffset="102-113" id="DDI-PubMed.15801541.s3.e2" text="simvastatin" /><entity charOffset="115-139" id="DDI-PubMed.15801541.s3.e3" text="cerivastatin fluvastatin" /><entity charOffset="141-153" id="DDI-PubMed.15801541.s3.e4" text="pitavastatin" /><entity charOffset="158-170" id="DDI-PubMed.15801541.s3.e5" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e0" e2="DDI-PubMed.15801541.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e0" e2="DDI-PubMed.15801541.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e0" e2="DDI-PubMed.15801541.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e0" e2="DDI-PubMed.15801541.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e0" e2="DDI-PubMed.15801541.s3.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e0" e2="DDI-PubMed.15801541.s3.e5" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e1" e2="DDI-PubMed.15801541.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e1" e2="DDI-PubMed.15801541.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e1" e2="DDI-PubMed.15801541.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e1" e2="DDI-PubMed.15801541.s3.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e1" e2="DDI-PubMed.15801541.s3.e5" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e2" e2="DDI-PubMed.15801541.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e2" e2="DDI-PubMed.15801541.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e2" e2="DDI-PubMed.15801541.s3.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e2" e2="DDI-PubMed.15801541.s3.e5" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e3" e2="DDI-PubMed.15801541.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e3" e2="DDI-PubMed.15801541.s3.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e3" e2="DDI-PubMed.15801541.s3.e5" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e4" e2="DDI-PubMed.15801541.s3.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s3.e4" e2="DDI-PubMed.15801541.s3.e5" /></sentence><sentence text=" A remarkable increase in metabolic clearance was noted for all lactones compared with all acids except for pitavastatin lactone"><entity charOffset="64-72" id="DDI-PubMed.15801541.s4.e0" text="lactones" /><entity charOffset="108-128" id="DDI-PubMed.15801541.s4.e1" text="pitavastatin lactone" /><pair ddi="false" e1="DDI-PubMed.15801541.s4.e0" e2="DDI-PubMed.15801541.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15801541.s4.e0" e2="DDI-PubMed.15801541.s4.e1" /></sentence><sentence text=" The metabolic clearances of the atrovastatin, simvastatin, cerivastatin, fluvastatin and rosuvastatin lactones were 73-, 70-, 30-, 7- and 64-fold higher, respectively, than those of the corresponding acids"><entity charOffset="33-45" id="DDI-PubMed.15801541.s5.e0" text="atrovastatin" /><entity charOffset="47-58" id="DDI-PubMed.15801541.s5.e1" text="simvastatin" /><entity charOffset="60-72" id="DDI-PubMed.15801541.s5.e2" text="cerivastatin" /><entity charOffset="74-85" id="DDI-PubMed.15801541.s5.e3" text="fluvastatin" /><entity charOffset="90-111" id="DDI-PubMed.15801541.s5.e4" text="rosuvastatin lactones" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e0" e2="DDI-PubMed.15801541.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e0" e2="DDI-PubMed.15801541.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e0" e2="DDI-PubMed.15801541.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e0" e2="DDI-PubMed.15801541.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e0" e2="DDI-PubMed.15801541.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e1" e2="DDI-PubMed.15801541.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e1" e2="DDI-PubMed.15801541.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e1" e2="DDI-PubMed.15801541.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e1" e2="DDI-PubMed.15801541.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e2" e2="DDI-PubMed.15801541.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e2" e2="DDI-PubMed.15801541.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e2" e2="DDI-PubMed.15801541.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e3" e2="DDI-PubMed.15801541.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15801541.s5.e3" e2="DDI-PubMed.15801541.s5.e4" /></sentence><sentence text=" CYP2Cs were critically involved in the metabolism of cerivastatin, fluvastatin and pitavastatin acids"><entity charOffset="54-66" id="DDI-PubMed.15801541.s6.e0" text="cerivastatin" /><entity charOffset="68-79" id="DDI-PubMed.15801541.s6.e1" text="fluvastatin" /><entity charOffset="84-102" id="DDI-PubMed.15801541.s6.e2" text="pitavastatin acids" /><pair ddi="false" e1="DDI-PubMed.15801541.s6.e0" e2="DDI-PubMed.15801541.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15801541.s6.e0" e2="DDI-PubMed.15801541.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15801541.s6.e0" e2="DDI-PubMed.15801541.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15801541.s6.e1" e2="DDI-PubMed.15801541.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15801541.s6.e1" e2="DDI-PubMed.15801541.s6.e2" /></sentence><sentence text=" In contrast, CYP2Cs were not involved in the metabolism of the corresponding lactones and CYP3A4 was mainly involved"><entity charOffset="78-86" id="DDI-PubMed.15801541.s7.e0" text="lactones" /></sentence><sentence text=" Moreover, a substantial difference in the metabolic inhibition of statins was found between acids and lactones"><entity charOffset="103-111" id="DDI-PubMed.15801541.s8.e0" text="lactones" /></sentence><sentence text=" Overall, the study demonstrates that CYP-mediated metabolism of lactones is also a common metabolic pathway for statins and that the CYP3A4-mediated metabolism of the lactone forms clearly will need to be taken into account in assessing mechanistic aspects of drug-drug interaction involving statins"><entity charOffset="65-73" id="DDI-PubMed.15801541.s9.e0" text="lactones" /><entity charOffset="168-175" id="DDI-PubMed.15801541.s9.e1" text="lactone" /><pair ddi="false" e1="DDI-PubMed.15801541.s9.e0" e2="DDI-PubMed.15801541.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15801541.s9.e0" e2="DDI-PubMed.15801541.s9.e1" /></sentence><sentence text="" /></document>